| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT07332481 A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or… |
Trial sites expanded: 13 -> 18 locations |
| 2026-08-15 | NCT07549412 A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to… |
Trial sites expanded: 21 -> 34 locations |
| 2026-08-14 | NCT04170153 Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid… |
date change Primary completion pushed: 2026-07-30 -> 2026-11-30 |
| 2026-08-14 | NCT04170153 Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid… |
date change Completion pushed: 2026-07-30 -> 2026-11-30 |
| 2026-08-13 | NCT06463587 Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in… |
Trial sites expanded: 145 -> 148 locations |
| 2026-08-12 | NCT06412848 JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study |
Trial completed |
| 2026-07-31 | NCT06710132 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE… |
Enrollment reduced: 250 -> 184 participants |
| 2026-07-31 | NCT05464030 Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) |
Enrollment closed, study ongoing |
| 2026-07-31 | NCT05464030 Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) |
Enrollment increased: 200 -> 220 participants |
| 2026-07-30 | NCT05081180 Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors |
critical Trial terminated |
| 2026-07-30 | NCT05081180 Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors |
critical Trial terminated: The study was stopped due to a lack of clear evidence of anti-tumor activity with the combination treatment in the part... |
| 2026-07-25 | NCT07549412 A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to… |
Trial sites expanded: 8 -> 21 locations |
| 2026-07-25 | NCT07340827 A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG… |
Trial sites expanded: 11 -> 21 locations |
| 2026-07-19 | NCT07355218 A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or… |
Trial sites expanded: 9 -> 13 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07355218 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or… | Systematic Lupus Erythematosus | Recruiting |
| NCT07340827 | A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG… | Infertility | Recruiting |
| NCT06463587 | Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in… | Generalized Myasthenia Gravis | Recruiting |
| NCT07332481 | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or… | Systemic Lupus Erythematosus (SLE) | Recruiting |
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to… | Metastatic Colorectal Cancer | Recruiting |
| NCT03815643 | Avelumab Program Rollover Study | Solid Tumors | Active, Not Recruiting |
| Phase 2 | |||
| NCT07499362 | Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT)… | Tenosynovial Giant Cell Tumor | Recruiting |
| NCT05327530 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in… | Locally Advanced or Metastatic Urothelial Carcinoma | Active, Not Recruiting |
| NCT06433219 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian… | Ovarian Cancer | Active, Not Recruiting |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC… | Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT02864992 | Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Active, Not Recruiting |
| NCT05540327 | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) | Systemic Lupus Erythematosus | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE… | Solid Tumors | Active, Not Recruiting |
| Phase 1 | |||
| NCT06577337 | Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants | Healthy | Recruiting |
| NCT07360314 | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | Advanced Solid Tumors | Recruiting |
| NCT07166601 | M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in… | Advanced Solid Tumor | Recruiting |
| NCT06641908 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | Advanced Solid Tumor | Recruiting |
| NCT05396833 | Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune… | Metastatic or Locally Advanced Unresectable Solid Tumors | Active, Not Recruiting |
| NCT06421935 | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | Advanced Solid Tumor | Active, Not Recruiting |
| NCT05464030 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | Colorectal Cancer | Active, Not Recruiting |
| NCT06806046 | Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors | Solid Tumors | Active, Not Recruiting |
| NCT04170153 | Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid… | Metastatic or Locally Advanced Unresectable Solid Tumors | Active, Not Recruiting |
| Not specified | |||
| NCT05376891 | Met Non Small Cell Cancer Registry (MOMENT) | Cancer | Recruiting |
| NCT05797740 | Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA) | Multiple Sclerosis | Active, Not Recruiting |